MAP2K7 and neoplasm: Their investigation further expanded to a series of naphthoquinone compounds (59a–i) with diverse substituent groups, evaluating their anticancer activities against nine tumor cell lines, inhibitory effects on MKK7 and MKK4, as well as Cdc25 A/B, complemented by molecular docking studies.